ABT vs DHR: Which Is the Better Buy in 2026?
Last updated October 2026
Short answer
ABT and DHR are similarly sized, but ABT trades noticeably cheaper on forward earnings (17.29x vs 24.64x): the market is paying up for DHR's profile and pricing ABT more conservatively, or for faster growth. Which you prefer comes down to the drivers you believe, and whether adding either over-concentrates what you already own.
ABT vs DHR: the tie-breaker metrics
Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | ABT | DHR | What it tells you |
|---|---|---|---|
| Market cap | $182.70B | $161.01B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 17.29 | 24.64 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 33.84 | 40.83 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.58 | 0.80 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 46% of range | 83% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 3.55 | 3.06 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: ABT is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how ABT and DHR affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ABT and DHR share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ABT and DHR exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Abbott Laboratories (ABT) do?
Abbott Laboratories is a global healthcare company headquartered in North Chicago, Illinois, that discovers, develops, manufactures, and sells health care products in more than 160 countries through four segments: Medical Devices, Diagnostic Products, Nutritional Products, and Established Pharmaceutical Products. Medical Devices, the largest segment at roughly $21.4 billion in 2025 revenue, includes the FreeStyle Libre family of continuous glucose monitors, structural heart products (Navitor, TriClip), electrophysiology systems (AVEIR leadless pacemaker, Volt pulsed field ablation, TactiFlex Duo), vascular devices, and heart-failure technologies (CardioMEMS). Diagnostics contributed roughly $8.9 billion in 2025 before the Exact Sciences deal, Nutrition roughly $8.5 billion (anchored by Similac infant formula and Ensure adult nutrition), and Established Pharmaceuticals roughly $5.5 billion in branded generics sold primarily in emerging markets.
What does Danaher Corporation (DHR) do?
Danaher Corporation is a global science and technology company built around three segments: Biotechnology (bioprocessing tools and consumables used to make biologic drugs, led by Cytiva and Pall), Life Sciences (instruments and reagents for research, including brands like Beckman Coulter Life Sciences, SCIEX, and Leica Microsystems), and Diagnostics (clinical and molecular testing through Beckman Coulter Diagnostics, Radiometer, Leica Biosystems, and Cepheid). A large share of revenue is recurring consumables and service tied to installed instruments and ongoing drug manufacturing, which is the core of the investment appeal. Danaher runs the well-known Danaher Business System, a continuous-improvement operating model it uses to drive margins and integrate acquisitions.
ABT vs DHR: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- ABT drivers: FreeStyle Libre: A Platform, Not Just a Product; Cardiovascular and Electrophysiology Momentum.
- DHR drivers: Bioprocessing recovery; Recurring consumables and razor-and-blade mix.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The most acute near-term risk is infant formula litigation: juries have delivered verdicts including a $53 million compensatory award in late March 2026 and a separately upheld $495 million verdict, with hundreds of additional NEC-related cases pending, and a securities class action filed in 2026 adds a parallel legal exposure track targeting alleged investor misstatements. For DHR, valuation is the most cited risk, since DHR often trades at a premium multiple (trailing P/E has ranged roughly from the mid-30s to mid-40s, and was about 41x on GAAP earnings with a forward P/E near 25x as of October 16, 2026), leaving little room for disappointment.
ABT or DHR: which should you pick?
ABT vs DHR: the full fundamentals
ABT. ABT's trailing GAAP P/E of about 34x is inflated by acquisition amortization and one-time costs from the Exact Sciences deal; on forward earnings the stock trades near 17x, well below its own 5-year and 10-year historical averages, after a roughly 16% decline in 2026. Revenue growth has remained positive, and the raised adjusted EPS guidance of $5.45-$5.60 implies a forward adjusted P/E of about 19x at the October 16 price of $104.44, below the average analyst target of about $121. Q3 2026 results are due October 21, with company guidance of $1.38-$1.46 adjusted EPS and consensus near $1.41 on about $13.0 billion of sales.
DHR. Danaher grew 2025 revenue about 2.9% to ~$24.6B with ~2% core growth, and growth picked up to about 5.5% in the second quarter of 2026. After a 29% three-month rally, the stock trades near 25x forward earnings and about 23x EV/EBITDA, the upper part of its usual premium range, with consensus EPS of about $8.51 for 2026 and $9.30 for 2027. The 22 analysts tracked by Yahoo Finance hold a strong buy consensus with a mean target near $244, close to the current price; figures are approximate and as of October 16, 2026.
Headline figures (approximate, October 2026): ABT shows revenue (ttm) ~$46.6 billion (Q2 2026 sales $12.59 billion, +13% reported, +4.8% comparable), revenue (fy 2025) ~$44.3 billion (+5.7% YoY), net income (ttm) ~$5.4 billion (GAAP EPS ~$3.10), net profit margin (ttm) ~11.7%; DHR shows revenue (ttm) ~$25.1B; Q2 2026 ~$6.26B (+5.5%), q2 2026 adj. eps $1.94 vs ~$1.84 estimate, margins (ttm) ~58.8% gross, ~19.8% operating, ~16.0% net, net income (ttm) ~$3.99B (GAAP EPS ~$5.61).
The bottom line: ABT vs DHR
ABT and DHR are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ABT and DHR exposure against your real portfolio. It is not an investment adviser.
Wondering how ABT or DHR fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Abbott Laboratories with AI
Connect the broker you already use and ask Walnut's AI how ABT fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between ABT and DHR?
+
Abbott Laboratories is a global healthcare company headquartered in North Chicago, Illinois, that discovers, develops, manufactures, and sells health care products in more than 160 countries through four segments: Medical Devices, Diagnostic Products, Nutritional Products, and Established Pharmaceutical Products. Danaher Corporation is a global science and technology company built around three segments: Biotechnology (bioprocessing tools and consumables used to make biologic drugs, led by Cytiva and Pall), Life Sciences (instruments and reagents for research, including brands like Beckman Coulter Life Sciences, SCIEX, and Leica Microsystems), and Diagnostics (clinical and molecular testing through Beckman Coulter Diagnostics, Radiometer, Leica Biosystems, and Cepheid). They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is ABT or DHR the better stock?
+
Neither is universally better; they suit different views and risk levels. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, ABT or DHR?
+
On forward P/E (as of October 2026), ABT trades at 17.29x and DHR at 24.64x, so ABT is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both ABT and DHR?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of ABT vs DHR?
+
ABT: The most acute near-term risk is infant formula litigation: juries have delivered verdicts including a $53 million compensatory award in late March 2026 and a separately upheld $495 million verdict, with hundreds of additional NEC-related cases pending, and a securities class action filed in 2026 adds a parallel legal exposure track targeting alleged investor misstatements. Abbott has started to narrow this exposure, reaching agreements in August 2026 to resolve a portion of the preterm-formula litigation and an agreement with the Department of Justice in September 2026 on claims tied to the 2022 recall, but the remaining liability is still open-ended. Integration of the approximately $21 billion Exact Sciences acquisition introduces execution risk, amortization and elevated SGA costs: GAAP EPS was only $0.53 in Q2 2026 against adjusted EPS of $1.31, and the trailing GAAP P/E is about 34x even though the forward multiple is about 17x. Organic growth also slowed to 4.8% in Q2 2026 on a comparable basis, below the full-year 6.5-7.5% guide. Foreign exchange swings move reported international revenue by several percentage points, and any meaningful dollar strengthening would pressure reported results disproportionately given Abbott's broad non-US exposure. Competitive disruption in continuous glucose monitoring from DexCom and emerging players, along with pricing pressure from government payers and the Inflation Reduction Act, represent structural long-term headwinds. DHR: Valuation is the most cited risk, since DHR often trades at a premium multiple (trailing P/E has ranged roughly from the mid-30s to mid-40s, and was about 41x on GAAP earnings with a forward P/E near 25x as of October 16, 2026), leaving little room for disappointment. Core revenue growth has been slow, around 2% for 2025 and roughly flat in early 2026, so the thesis leans heavily on the bioprocessing recovery arriving on schedule. Biopharma and academic funding cycles, hospital and diagnostics testing volumes, and currency swings all move results. China demand and policy, along with broader biotech funding conditions, are additional swing factors. As a diversified conglomerate, weakness in any one segment can offset strength elsewhere. After a roughly 29% three-month rally into the October 21 report, the shares also carry more near-term expectation risk than they did at the summer lows. Total debt of about $27.9 billion against about $4.4 billion of cash is manageable for a company of this size but limits how large the next acquisition can be without more borrowing.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ABT or DHR; figures are approximate and dated (as of October 2026). Verify current data before investing.